[1]凌 玲,桑学涵,尹 静,等.卵巢浆液性腺癌组织锌指蛋白变体(Ciz1-V蛋白)的表达与患者预后的相关性研究[J].现代检验医学杂志,2019,34(05):32-34.[doi:10.3969/j.issn.1671-7414.2019.05.009]
　LING Ling,SANG Xue-han,YIN Jing,et al.Correlation between the Expression of Ciz1-V in Ovarian Serous Adenocarcinoma and Prognosis of Patients[J].Journal of Modern Laboratory Medicine,2019,34(05):32-34.[doi:10.3969/j.issn.1671-7414.2019.05.009]
点击复制

卵巢浆液性腺癌组织锌指蛋白变体(Ciz1-V蛋白)的表达与患者预后的相关性研究()

《现代检验医学杂志》[ISSN:/CN:]

卷:
第34卷
期数:
2019年05期
页码:
32-34
栏目:
论著
出版日期:
2019-10-29

文章信息/Info

Title:
Correlation between the Expression of Ciz1-V in Ovarian Serous Adenocarcinoma and Prognosis of Patients
文章编号:
1671-7414(2019)05-032-04
作者:
凌 玲1,2,桑学涵3,尹 静1,谢凌云1,成颖1,程文国1
(1.扬州大学医学院附属医院扬州市妇幼保健院,江苏扬州 225000; 2.扬州大学医学院江苏省非编码RNA基础与临床转化重点实验室,江苏扬州 225000; 3.江苏省苏北人民医院,江苏扬州 225000)
Author(s):
LING Ling1,2,SANG Xue-han3,YIN Jing1,XIELing-yun1,CHENG Ying1,CHENG Wen-guo 1
(1.the Affiliated Hospital to Yangzhou Medical College,YangzhouWomen and Children Hospital, Jiangsu Yangzhou 225000,China; 2.Jiangsu Key Laboratory of Experimental& Translational Non-coding RNA Research,Medical Department,Yangzhou University,JiangsuYangzhou 225000,China; 3.Subei People's Hospital of Jiangsu Province,Jiangsu Yangzhou 225000,China)
关键词:
卵巢浆液性腺癌;  锌指蛋白变体-V蛋白;  肿瘤分期;  肿瘤分级
分类号:
R737.31; R730.43
DOI:
10.3969/j.issn.1671-7414.2019.05.009
文献标志码:
A
摘要:
目的 研究锌指蛋白变体V(Ciz1-V蛋白)表达水平在卵巢浆液性腺癌患者预后评估中的临床意义。方法 选取2005～2014年扬州大学医学院附属扬州市妇幼保健院和南京医科大学附属逸夫医院40例卵巢浆液性腺癌患者,回顾性分析FIGO分期和肿瘤分级对其预后的影响,同时采用免疫组织化学法检测Ciz1-V蛋白的表达,绘制Kaplan-Meier生存曲线,筛选预后相关因素。结果 Kaplan-Meier生存曲线显示,该实验中FIGO分期与生存期之间不具有统计学意义(P=0.08),高、低级别卵巢浆液性腺癌患者之间的差异有统计学意义(P=0.035)。在40例卵巢浆液性腺癌患者中,Ciz1-V蛋白低表达组预后明显较Ciz1-V蛋白高表达组预后差,差异有统计学意义(P=0.016)。结论 卵巢浆液性腺癌肿瘤分级越高,其生物学行为愈差,生存率越低。当患者肿瘤分级相同时,检测Ciz1-V蛋白的表达水平对于预测患者预后有价值。
Abstract:
Objective To research the expression of Ciz1-Vprotein in patients with ovarian serous adenocarcinoma.Methods Specimens of 40 patients with ovarian serous adenocarcinoma in YangzhouMaternal and Child Care Service Centre of the Affiliated Hospital of Medical College of Yangzhou University,and Yifu Hospital Affiliated to Nanjing Medical University were selected from 2005 to 2014.A retrospective analysis was made of FIGOstaging and tumor grading on the prognosis,meanwhile,the expression of Ciz1-V protein was detected by immunohistochemical method and the prognostic factorswere screened by Kaplan-Meier survival curve.Results The Kaplan-meier survival curve showed that there was no significant difference between the FIGO staging and the survival time(P=0.08)and the prognosis ofpatients with low grade ovarian serous adenocarcinoma was significantly betterthan patients with high-grade ovarian serous adenocarcinoma(P=0.035).In40 patients with ovarian serous adenocarcinoma,patients with higher level of Ciz1-V protein had a better survival rate than patients with lower level of Ciz1-V protein(P=0.016).Conclusion The higher the tumor grading,the worse the biological behavior and the lower the survival rate ofovarian serous adenocarcinoma.When the tumor grading is the same,the expression of Ciz1-V protein is valuable to predict the prognosis of patients.

参考文献/References:

[1] SHARADHA S,SRIDEVI T A,RENUKADEVI T K,et al.Qvarian masses:Changing clinico histopathological trends[J].J Obstet Gynaecol India,2015,65(1):34-38. [2] 凌玲,苏东明.Ciz1-V蛋白在卵巢浆液性腺癌中的表达及临床意义[J].江苏医药,2017,43(18):1299-1301. LING Ling,SU Dongming.Expression and significance of Ciz1-V protein in ovarian serous adenocarcinoma[J].Jiangsu Medical Journal,2017,43(18):1299-1301. [3] 佐晶,宋艳,李卓,等.P53蛋白表达与晚期卵巢浆液性腺癌预后的相关性[J].中国医学科学院学报,2016,38(2):169-174. ZUO Jing,SONG Yan,LI Zhuo,et al.Relationship between P53 proteinexpression and prognosis of advanced ovarian serous adenocarcinoma[J].Acta Academiae Medicinae Sinicae,2016,38(2):169-174. [4] 李力,陈昌贤.晚期卵巢上皮性癌新辅助化疗若干问题的思考[J].中华妇产科杂志,2018,53(2):73-76. LI Li,CHEN Changxian.Thoughts on several problems of neoadjuvant chemotherapy for advanced ovarian epithelial cancer[J].Chinese Journal of Obstetrics and Gynecology,2018,53(2):73-76. [5] 刘青,邓慧敏,周林涛,等.卵巢癌患者组织中miR-135b的表达及临床意义[J].现代检验医学杂志,2019,34(2):32-34. LIU Qing,DENG Huimin,ZHOU Lintao,et al.Expression and clinical significance of miR-135b in tissues of patients with ovarian cancer[J].Journal Modern Laboratory Medicine,2019,34(2):32-34. [6] 王瀚,高雪梅,杜娟.真核细胞起始因子3和人附睾蛋白4在卵巢癌组织中的表达及临床意义[J].实用临床医药杂志,2017,21(11):97-100. WANG Han,GAO Xuemei,DU Juan.Expressions and significance of eukaryotic initiation factor 3 and human epididymis protein 4 in ovarian cancer tissues[J].Journal of Clinical Medicine in Practice,2017,21(11):97-100. [7] MILLER J,MCLACHLAN A D,KLUG A.Repetitive zinc-binding domains in theprotein transcription factor IIIA from Xenopus oocytes[J].Embo Journal,1985,4(6):1609-1614. [8] WANG Dongqing,WANG Kun,YAN Dongwang,et al.Ciz1 is a novel predictor of survival in human colon cancer[J].Exp Biol Med,2014,239(7):862-870. [9] LIU Tao,REN Xiaohui,LI Lin,et al.Ciz1 promotes tumorigenicity of prostate carcinoma cells[J].Front Biosci,2015,20(4),705-715. [10] LEI Liu,WU Jinsheng,GU Dianhua,et al.Ciz1 interacts with YAPand activates its transcriptional activity in hepatocellular carcinoma cells[J].Tumour Biol,2016,37(8):11073-11079. [11] ZHANG Dexiang,WANG Yueqi,DAI Yuedi,et al.Ciz1 promoted the growth and migration of gallbladder cancer cells[J].Tumour Biol,2015,36(4):2583-2591. [12] 曹娅,华子春,徐根兴.人复制蛋白变体胶乳增强免疫检测试剂盒的研制[J].药物生物技术,2015,22(3):203-206. CAO Ya,HUA Zichun,XU Genxing.Development of latex paticle enhanced immunoassay kit for human Ciz1-V[J].Pharmaceutical Biotechnology,2015,22(3):203-206.

备注/Memo

备注/Memo:
基金项目:江苏省扬州市级项目(编号:YZ2018080)。 作者简介:凌 玲(1989-),女,博士在读,主管检验师,临床检验诊断方向,E-mail:237287542@qq.com。 通讯作者:程文国,E-mail:573497482@qq.com。
更新日期/Last Update: 2019-10-20